GSK’s Blenrep Gains US FDA Approval for Blood Cancer Treatment
TL;DR Summary
The US FDA has approved GSK's Blenrep in combination with bortezomib and dexamethasone for treating relapsed/refractory multiple myeloma in patients who have received at least two prior therapies, based on positive results from the DREAMM-7 trial showing significant survival benefits. Blenrep is notable for its community accessibility and ongoing development in earlier treatment lines.
- Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma GSK
- US FDA approve GSK's blood cancer treatment Reuters
- FDA delivers split decision on GSK’s blood cancer drug Blenrep, approving its use in some cases statnews.com
- US health agency reapproves GSK blood cancer drug after new trial Financial Times
- GSK’s Blood Cancer Drug Blenrep Wins US Regulatory Approval Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
9 min
vs 10 min read
Condensed
97%
1,850 → 54 words
Want the full story? Read the original article
Read on GSK